Ultrastructural study in canine prostatic hyperplasia effect of antiandrogen

Tokai Journal of Experimental and Clinical Medicine

Volumn 23, Issue 5, 1998, Pages 245-248

  Murakoshi, Masanori ^a   Masuda, Shuuji ^b   Ikeda, Rie ^b   Tagawa, Masashi ^b   Nakayama, Takaharu ^b   Honma, Seijiroh ^b   Mieda, Mamoru ^b  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b NONE

Author keywords

Benign prostatic hyperplasia (BPH); Chlormadinone acetate (CMA); Glandular epithelium; Mitochondria; Smooth muscle cell

Indexed keywords

ANTIANDROGEN; CHLORMADINONE ACETATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; ATROPHY; CONTROLLED STUDY; CYTOPLASM; DOG; DRUG EFFECT; EXOCYTOSIS; GOLGI COMPLEX; MALE; MITOCHONDRION SWELLING; NONHUMAN; ORAL DRUG ADMINISTRATION; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; ROUGH ENDOPLASMIC RETICULUM; SECRETORY GRANULE; ULTRASTRUCTURE;

ANIMALS; CHLORMADINONE ACETATE; DOGS; MALE; PROGESTERONE CONGENERS; PROSTATE; PROSTATIC HYPERPLASIA;

EID: 0032419478     PISSN: 03850005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Amuller G., Braun B.E., Seity J: Effect of sexual rest or sexual activity on the structure and function of the ventral prostate of the rat. Anat Rec 212: 345-352, 1985.
2. Habenicht V.F., El Etreby M.F: Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs. Prostate 11 : 133-143, 1987.
3. Ito Y., Kurokawa I., Yamanaka H: The mechanism of antiandrogenic action of chlormadinone acetate. Hinyokika Kiyo 68: 537-552, 1977.
4. McNeal J.E: The pathobiology of nodular prostatic hyperplasia in the human. In: NIH, No.87: 2881, CH Rodgers, DS Coffey, G Cunha, JT Grayhack, F Hinman, and R Horton (eds), Bethesda 101-108, 1987.
5. Murakoshi M., Inada R., Tagawa M., Makino M., Suzuki M., Mieda M., Honma S., Takezawa Y., Yamanaka H: Inhibitory influence of a new steroidal antiandrogen, TZP-4238, on prostatic hyperplasia in the beagle dog. Acta Pathol Jpn 42: 151-157, 1992.
6. Murakoshi M., Tagawa M., Inada R., Shoji M., Suzuki M., and Watanabe K: The effect of new steroidal antiandrogen, TZP-4238, and chlormadinone acetate on the pituitary, prostate and adrenal gland of the rat. Histopathological and immunocytochemical studies. Endocrinol Japon 39: 331-340, 1992.
7. Murakoshi M., Ikeda R., Tagawa M., Nakayama T., Honma S., Mieda M: Immunolocalization of androgen receptor in canine prostatic hyperplasia. Effect of antiandrogen. Tokai J Exp Clin Med 23: 209-212, 1998.
8. Okada K., Oishi K., and Yoshida O: Study of the effect of an antiandrogen (oxendrolone) on experimentally induced canine prostatic hyperplasia. Urol Res 16 : 67-72, 1988.
9. Tunn S., Hochstrate H., Habenicht V.F., Krieg M: 5 a-reductase activity in epithelium and stroma of prostates from intact and castrated dogs treated with androstadiene-3, 17-dione, and cyproterone acetate. Prostate 12: 243-253, 1988.
10. Weber J.P., Oesterling J.E., Peters C.A., Partin A.W., Chan D.W., Walsh P.C: The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 141: 987-992, 1989.